Fennec Pharmaceuticals Inc.

FENC | NASDAQ

Price Alert Chart Builder DCF Calculator

$10.91

+$0.29 (+2.73%)

At close: Sep 21, 2026, 4:00 PM ET

$10.91

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.73%

(1D)

Rating

Updated: Sep 4, 2026

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $378.98M

1D Range

10.64 10.94

52W Range

5.65 13.25

Valuation (TTM)

PE -77.93

PB 8.93

EV/EBITDA -142.14

Valuation (NTM)

Forward PE 12.43

Forward PEG -0.36

Price Target $16

Cash Flow

FCF Yield -0.5%

SBC Adj. FCF Yield -2.3%

SBC Impact -319.4%

Margins

Gross Margin 93.7%

Operating Margin -2.0%

FCF Margin -3.4%

Growth (CAGR)

Revenue 3Y | 5Y 108.5% | 222.4%

Dil EPS 3Y | 5Y -50.9% | 37.7%

FCF 3Y | 5Y -403.8% | 62.3%

Returns

ROA -4.3%

ROE -11.7%

ROIC -1.8%

Financial Health

Net Cash

$41.25M

Current Ratio 5.85

Interest Coverage -1.29

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment i...

Sector Healthcare

Industry Biotechnology

Employees 35

IPO Date Sep 14, 2017

Website www.fennecpharma.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$16

Upside

+46.65%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞